A COST VARIATION COMPARISON AMONG ORAL ANTI-MIGRAINE DRUGS AVAILABLE IN THE INDIAN MARKET

International Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-05-01 DOI:10.22159/ijpps.2024v16i5.50777

Akash Mishra, P. S. Mishra, Anjali Kushwah, Kamayani Gupta

{"title":"A COST VARIATION COMPARISON AMONG ORAL ANTI-MIGRAINE DRUGS AVAILABLE IN THE INDIAN MARKET","authors":"Akash Mishra, P. S. Mishra, Anjali Kushwah, Kamayani Gupta","doi":"10.22159/ijpps.2024v16i5.50777","DOIUrl":null,"url":null,"abstract":"Objective: Our study aimed to evaluate the cost percent variation and cost ratio of different brands of oral anti-migraine drugs available in Indian market.\nMethods: The cost of various commonly used oral anti-migraine drugs were taken from the latest issue of Current Index of Medical Specialities January 2022, Drug Today January-April 2022 and 1 mg online site. Cost percent variation and Cost ratio were calculated.\nResults: A total of 7 single anti-migraine drugs and 9 Fixed-Dose Combinations (FDCs) showed a wide range of cost variation. The highest cost percent variation of 433% was seen in Sumatriptan 50 mg with a cost ratio of 5.33, whereas Amitriptyline 10 mg showed the lowest cost percent variation of 47.9% with a cost ratio of 1.47. Among FDCs Naproxen 500 mg+Sumatriptan 85 mg showed the highest cost per cent variation of 400% with a cost ratio of 5.25 and Propranolol 40 mg+Flunarizine 10 mg showed the lowest cost per cent variation of 46.56% with a cost ratio of 1.46.\nConclusion: Our study showed a wide variation in the cost of oral anti-migraine drugs available in the Indian market, which provides insight to the healthcare professional and gives Drug Price Control Order (DPCO) authorities to minimize the financial burden and improve patient compliance.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"1 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmacy and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22159/ijpps.2024v16i5.50777","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Our study aimed to evaluate the cost percent variation and cost ratio of different brands of oral anti-migraine drugs available in Indian market. Methods: The cost of various commonly used oral anti-migraine drugs were taken from the latest issue of Current Index of Medical Specialities January 2022, Drug Today January-April 2022 and 1 mg online site. Cost percent variation and Cost ratio were calculated. Results: A total of 7 single anti-migraine drugs and 9 Fixed-Dose Combinations (FDCs) showed a wide range of cost variation. The highest cost percent variation of 433% was seen in Sumatriptan 50 mg with a cost ratio of 5.33, whereas Amitriptyline 10 mg showed the lowest cost percent variation of 47.9% with a cost ratio of 1.47. Among FDCs Naproxen 500 mg+Sumatriptan 85 mg showed the highest cost per cent variation of 400% with a cost ratio of 5.25 and Propranolol 40 mg+Flunarizine 10 mg showed the lowest cost per cent variation of 46.56% with a cost ratio of 1.46. Conclusion: Our study showed a wide variation in the cost of oral anti-migraine drugs available in the Indian market, which provides insight to the healthcare professional and gives Drug Price Control Order (DPCO) authorities to minimize the financial burden and improve patient compliance.

查看原文本刊更多论文

印度市场上抗偏头痛口服药物的成本差异比较

研究目的我们的研究旨在评估印度市场上不同品牌的抗偏头痛口服药物的成本百分比变化和成本比率：方法：从最新一期的《Current Index of Medical Specialities》（2022 年 1 月）、《Drug Today》（2022 年 1-4 月）和 1 mg 在线网站上获取各种常用口服抗偏头痛药物的成本。计算了成本百分比变化和成本比率：结果：共有 7 种单一抗偏头痛药物和 9 种固定剂量复方制剂（FDC）的成本差异较大。舒马曲普坦 50 毫克的成本变化率最高，达 433%，成本比为 5.33；阿米替林 10 毫克的成本变化率最低，为 47.9%，成本比为 1.47。在 FDCs 中，萘普生 500 毫克+舒马曲普坦 85 毫克的成本百分比差异最大，为 400%，成本比为 5.25；普萘洛尔 40 毫克+氟桂利嗪 10 毫克的成本百分比差异最小，为 46.56%，成本比为 1.46：我们的研究表明，印度市场上抗偏头痛口服药物的成本差异很大，这为医疗保健专业人士和《药品价格管理条例》（DPCO）制定机构提供了深入的见解，以最大限度地减轻患者的经济负担，提高患者的依从性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Pharmacy and Pharmaceutical Sciences

自引率

0.00%

发文量